OncRef

Clinical Trial: NCT07295951

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:Janssen Research & Development, LLC
Information Provided By:Janssen Research & Development, LLC
Last Update Posted:2026-09-25

Study Overview

Brief Summary

The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow).

Official Title

An Open-Label Study to Investigate the Absorption, Metabolism, And Excretion (AME) Of 14C-Bleximenib (JNJ-75276617) in Participants With Acute Leukemia

Conditions

Acute Lymphoblastic Leukemia, Acute Leukemias, Acute Myeloid Leukemia

Intervention / Treatment

  • Drug: 14C-bleximenib
  • Drug: bleximenib

Other Study ID Numbers

  • 75276617ALE1006
  • 75276617ALE1006

Start Date (Actual)

2025-11-18

Primary Completion Date (Actual)

2026-07-21

Study Completion Date (Actual)

2026-07-21

Enrollment (Actual)

6

Study Type

Interventional

Phase

Phase 1